Journal of Gastroenterology and Hepatology,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 3, 2024
Abstract
There
is
increasing
evidence
that
cannabidiol
(CBD)
use
associated
with
clinically
significant
liver
enzyme
(LE)
elevations
and
drug‐induced
injury
(DILI).
The
proportion
of
LE
DILI
events
reported
in
the
literature
meet
Council
for
International
Organizations
Medical
Sciences'
(CIOMS)
classification
a
common
adverse
drug
reaction.
However,
these
potential
are
unknown
to
many
clinicians
may
be
overlooked.
CBD
both
medical
non‐medical
necessitates
clear
direction
diagnosis
management
CBD‐associated
hepatotoxicity.
To
our
knowledge,
no
such
clinical
guidance
currently
exists.
For
people
presenting
elevated
LEs,
should
screened
considered
differential
diagnosis.
This
narrative
review
will
provide
prevention,
detection,
CBD‐related
Journal of Clinical Oncology,
Год журнала:
2024,
Номер
42(13), С. 1575 - 1593
Опубликована: Март 13, 2024
To
guide
clinicians,
adults
with
cancer,
caregivers,
researchers,
and
oncology
institutions
on
the
medical
use
of
cannabis
cannabinoids,
including
synthetic
cannabinoids
herbal
derivatives;
single,
purified
cannabinoids;
combinations
ingredients;
full-spectrum
cannabis.
Journal of Environmental Science and Health Part C,
Год журнала:
2024,
Номер
42(3), С. 238 - 254
Опубликована: Июнь 21, 2024
Increasing
public
interest
has
resulted
in
the
widespread
use
of
non-pharmaceutical
cannabidiol
(CBD)
products.
The
sales
CBD
products
continue
to
rise,
accompanied
by
concerns
regarding
unsubstantiated
benefits,
lack
product
quality
control,
and
potential
health
risks.
Both
animal
human
studies
have
revealed
a
spectrum
toxicological
effects
linked
CBD.
Adverse
related
exposure
humans
include
changes
appetite,
gastrointestinal
discomfort,
fatigue,
elevated
liver
aminotransferase
enzymes.
Animal
reported
organ
weight,
reproduction,
function,
immune
system.
This
review
centers
on
human-derived
data,
including
clinical
Chronic
pain
represents
a
complex
and
debilitating
condition
that
affects
millions
of
people
worldwide,
significantly
compromising
their
quality
life.
The
conventional
approach
to
treating
this
type
often
relies
on
the
use
opioid
analgesics
anti-inflammatory
drugs.
While
these
agents
are
effective
in
short
term,
they
present
several
limitations,
including
risk
dependence,
severe
side
effects,
and,
some
cases,
ineffectiveness
reducing
pain.
In
context,
medical
cannabis
has
emerged
as
promising
therapeutic
alternative,
given
its
potential
ability
relieve
effectively
with
favorable
safety
profile.
This
work
aims
provide
comprehensive
up-to-date
review
existing
literature
effects
treatment
chronic
Cannabis
sativa
contains
pharmacologically
active
compounds,
most
prominent
which
delta-9-tetrahydrocannabinol
(∆9-THC)
cannabidiol
(CBD),
interact
body’s
endocannabinoid
system,
thereby
modulating
response.
Clinical
evidence
shown
cannabinoids
can
reduce
intensity
pain,
particularly
cases
neuropathy,
multiple
sclerosis,
arthritis,
other
painful
conditions
unresponsive
treatments.
However,
full
integration
into
clinical
practice
faces
significant
obstacles,
need
for
standardized
dosing,
long-term
data,
regulatory
frameworks.
These
issues,
alongside
concerns
over
adverse
drug
interactions,
must
be
addressed
unlock
cannabinoids,
patients,
who
endure
both
physical
suffering
added
burden
stress.
Drug Metabolism and Disposition,
Год журнала:
2024,
Номер
52(6), С. 508 - 515
Опубликована: Янв. 29, 2024
Cannabidiol
(CBD)
is
a
pharmacologically
active
metabolite
of
cannabis
that
FDA-approved
to
treat
seizures
associated
with
Lennox-Gastaut
syndrome,
Dravet
and
tuberous
sclerosis
complex
in
children
aged
one
year
older.
During
clinical
trials,
CBD
caused
dose-dependent
hepatocellular
toxicity
at
therapeutic
doses.
The
risk
for
was
increased
patients
taking
valproate
(VPA),
another
hepatotoxic
antiepileptic
drug,
through
an
unknown
mechanism.
With
the
growing
popularity
consumer
market,
improved
understanding
safety
risks
needed
ensure
public
health.
This
review
details
current
efforts
describe
pharmacokinetics
mechanisms
hepatotoxicity
using
both
pharmacokinetic
models
in
vitro
liver.
In
addition,
evidence
knowledge
gaps
related
intracellular
CBD-induced
are
described.
authors
propose
future
directions
combine
systems-based
markers
understand
how
may
influence
adverse
effect
profile
liver
injury
those
CBD.
Significance
Statement
describes
modeling
approaches
capture
metabolic
clearance
cannabidiol
(CBD).
increasingly
popular
natural
product
drug
known
cause
clinically
significant
enzyme-mediated
interactions
metabolism,
pharmacokinetics,
putative
summarized
from
available
preclinical
data
inform
toxicity.
Journal of Pain,
Год журнала:
2023,
Номер
25(4), С. 833 - 842
Опубликована: Окт. 18, 2023
Cannabidiol
(CBD)
attracts
considerable
attention
for
promoting
good
health
and
treating
various
conditions,
predominantly
pain,
often
in
breach
of
advertising
rules.
Examination
available
CBD
products
North
America
Europe
demonstrates
that
content
can
vary
from
none
to
much
more
than
advertised
potentially
harmful
other
chemicals
are
included.
Serious
harm
is
associated
with
found
reported
children,
adults,
the
elderly.
A
2021
International
Association
Study
Pain
task
force
examined
evidence
cannabinoids
pain
but
no
trials
CBD.
Sixteen
randomized
using
pharmaceutical-supplied
or
making
preparations
such
a
source
as
an
outcome
have
been
published
subsequently.
The
were
conducted
12
different
states,
3
oral,
topical,
buccal/sublingual
administration,
doses
between
6
1,600
mg,
durations
treatment
single
dose
weeks.
Fifteen
16
showed
benefit
over
placebo.
Small
clinical
verified
suggest
drug
be
largely
benign;
while
large-scale
safety
lacking,
there
growing
linking
increased
rates
serious
adverse
events
hepatotoxicity.
In
January
2023,
Food
Drug
Administration
(FDA)
announced
new
regulatory
pathway
was
needed.
Consumers
care
providers
should
rely
on
evidence-based
sources
information
CBD,
not
just
advertisements.
Current
expensive,
ineffective,
possibly
harmful.
PERSPECTIVE:
There
reason
thinking
relieves
reasons
doubting
contents
terms
purity.
Biomedicine & Pharmacotherapy,
Год журнала:
2024,
Номер
177, С. 116969 - 116969
Опубликована: Июнь 21, 2024
Cannabidiol
(CBD),
a
naturally
occurring
cyclic
terpenoid
found
in
Cannabis
sativa
L.,
is
renowned
for
its
diverse
pharmacological
benefits.
Marketed
as
remedy
various
health
issues,
CBD
products
are
utilized
by
patients
supplementary
therapy
or
post-treatment
failure,
well
healthy
individuals
seeking
promised
advantages.
Despite
widespread
use,
information
regarding
potential
adverse
effects,
especially
genotoxic
properties,
limited.
The
present
study
focused
on
the
mutagenic
and
activity
of
isolate
(99.4
%
content)
CBD-rich
L
extract
(63.6
vitro.
Both
samples
were
non-mutagenic,
determined
AMES
test
(OECD
471)
but
exhibited
cytotoxicity
HepG2
cells
(∼IC
Toxicology,
Год журнала:
2024,
Номер
506, С. 153885 - 153885
Опубликована: Июль 14, 2024
Cannabidiol
(CBD)
has
been
reported
to
induce
hepatotoxicity
in
clinical
trials
and
research
studies;
however,
little
is
known
about
the
safety
of
other
nonintoxicating
cannabinoids.
New
approach
methodologies
(NAMs)
based
on
bioinformatic
analysis
high-throughput
transcriptomic
data
are
gaining
increasing
importance
risk
assessment
regulatory
decision-making
data-poor
chemicals.
In
current
study,
we
conducted
a
concentration
response
hemp
extract
its
four
major
constituent
cannabinoids
[CBD,
cannabichromene
(CBC),
cannabigerol
(CBG),
cannabinol
(CBN)]
hepatocytes
derived
from
human
induced
pluripotent
stem
cells
(iPSCs).
Each
compound
impacted
distinctive
combination
biological
functions
pathways.
However,
all
impaired
liver
metabolism
caused
oxidative
stress
cells.
Benchmark
(BMC)
showed
potencies
transcriptional
activity
were
order
CBN
>
CBD
CBC
CBG,
consistent
with
their
cytotoxicity
IC
Biomedicine & Pharmacotherapy,
Год журнала:
2023,
Номер
165, С. 115074 - 115074
Опубликована: Июль 6, 2023
Aging
is
usually
considered
a
key
risk
factor
associated
with
multiple
diseases,
such
as
neurodegenerative
cardiovascular
diseases
and
cancer.
Furthermore,
the
burden
of
age-related
has
become
global
challenge.
It
great
significance
to
search
for
drugs
extend
lifespan
healthspan.
Cannabidiol
(CBD),
natural
nontoxic
phytocannabinoid,
been
regarded
potential
candidate
drug
antiaging.
An
increasing
number
studies
have
suggested
that
CBD
could
benefit
healthy
longevity.
Herein,
we
summarized
effect
on
aging
analyzed
possible
mechanism.
All
these
conclusions
may
provide
perspective
further
study
aging.
